T3787
3,3′,5,5′-四硫代甲酰乙酸
≥98% (TLC), powder, thyrointegrin receptor antagonist
别名:
4-（4-羟基-3,5-二碘苯氧基）-3,5-二碘苯乙酸, Tetrac
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
C14H8O4I4
化学文摘社编号:
分子量:
747.83
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352106
EC Number:
200-649-1
MDL number:
产品名称
3,3′,5,5′-四硫代甲酰乙酸,
InChI key
PPJYSSNKSXAVDB-UHFFFAOYSA-N
InChI
1S/C14H8I4O4/c15-8-4-7(5-9(16)13(8)21)22-14-10(17)1-6(2-11(14)18)3-12(19)20/h1-2,4-5,21H,3H2,(H,19,20)
SMILES string
OC(=O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1
solubility
acetone: soluble 19.60-20.40 mg/mL, clear, colorless (or faintly yellow to yellow)
storage temp.
−20°C
Quality Level
相关类别
Application
3,3′,5,5′-四碘甲腺乙酸已被用于：
- 作为阳性对照研究碘苯腈 (IOX)
- 二乙基己烯雌酚 (DES) 暴露对斑马鱼胚胎的影响
- 研究其对聚氨酯麻醉的雄性大鼠齿状回的长期增益 (LTP) 和长期抑制 (LTD) 作用
- 确定其对眼眶成纤维细胞中促甲状腺激素
- 促甲状腺免疫球蛋白的作用的影响。
Biochem/physiol Actions
3,3′,5,5′-四碘甲腺乙酸 (Tetrac) 是一种L-甲状腺素 （T4）的 脱氨基类似物。 它可以防止T4和3,5,3′-三碘-L-甲腺原氨酸的促血管生成作用。 它是甲状腺整合素受体的拮抗剂。Tetrac可防止甲状腺激素的结合。
对大鼠的研究报道了 Tetrac 可能在体内条件下调节 TSH 分泌1。
Other Notes
甲状腺激素类似物
Preparation Note
3,3′,5,5′-四硫代甲基乙酸以 19.60-20.40 mg/ml 溶于丙酮，并形成一种透明的淡黄色至黄色溶液。
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 2 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
法规信息
涉药品监管产品
此项目有
Tetrac and NDAT induce Anti-proliferation via Integrin alphavbeta3 in Colorectal Cancers with Different K-RAS Status
Chin YT, et al.
Frontiers in Endocrinology, 10, 130-130 (2019)
Paul J Davis et al.
Annual review of pharmacology and toxicology, 51, 99-115 (2010-09-28)
Plasma membrane integrin αvβ3 is a cell surface receptor for thyroid hormone at which nongenomic actions are initiated. L-thyroxine (T₄) and 3,3',5-triiodo-L-thyronine (T₃) promote angiogenesis and tumor cell proliferation via the receptor. Tetraiodothyroacetic acid (tetrac), a deaminated T₄ derivative, blocks
Elevated serum tetrac in Graves disease: potential pathogenic role in thyroid-associated ophthalmopathy
Fernando R, et al.
The Journal of clinical endocrinology and metabolism, 102(3), 776-785 (2016)
Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer
Rajabi M, et al.
Bioorganic & Medicinal Chemistry Letters, 28(7), 1223-1227 (2018)
M Yalcin et al.
The Journal of clinical endocrinology and metabolism, 95(4), 1972-1980 (2010-02-06)
Tetraiodothyroacetic acid (tetrac) blocks angiogenic and tumor cell proliferation actions of thyroid hormone initiated at the cell surface hormone receptor on integrin alphavbeta3. Tetrac also inhibits angiogenesis initiated by vascular endothelial growth factor and basic fibroblast growth factor. We tested
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持